Primary non-Hodgkin's lymphoma and pseudolymphoma of lung: A study of 161 patients

Koss, Michael N.; Hochholzer, Liselotte; Nichols, Peter W.; Wehunt, William D.; Lazarus, Angeline A.

doi:10.1016/s0046-8177(83)80258-5

Cited by 186 publications

(127 citation statements)

References 27 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…Malignant transfor mation of pseudolymphomas in the lung [21] and stomach [22] have been reported. These reports, however, either predated or did not include the use of immunofluorescent techniques.…”

Section: Discussionmentioning

confidence: 99%

Pseudolymphoma of the liver associated with primary biliary cirrhosis: A case report and review of literature

Okada¹,

Mibayashi²,

Hasatani³

et al. 2009

WJG

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Pseudolymphoma of the liver associated with primary biliary cirrhosis: A case report and review of literature

Okada¹,

Mibayashi²,

Hasatani³

et al. 2009

WJG

View full text Add to dashboard Cite

“…[14][15][16][17][18][19][20][21][22][23][24][25] Two outcome studies, 26 20 In patients with MALT type lymphoma the overall survival at one year was 91%, the overall survival at five years was 68% and the overall survival at ten years was 53%. These data were weighted taking into account the fact that this lymphoma is an indolent disease usually with a long natural course, and that it is a multifocal disease in which a radical resection is not easy to perform.…”

Section: Primary Lung Lymphomasmentioning

confidence: 99%

Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation

Zinzani¹,

Martelli²,

Poletti³

et al. 2008

Haematologica

View full text Add to dashboard Cite

Extranodal non-Hodgkin's lymphomas constitute 20-25% of overall non-Hodgkin's lymphomas cases and can be managed with very different therapeutic strategies. Therefore, the Italian Society of Hematology and the two affiliate societies (the Italian Society of Experimental Hematology and the Italian Group of Bone Marrow Transplantation) appointed a panel of experts to produce clinical practice-guidelines for the management of these conditions. Primary lung and mediastinal lymphomas were the objective of this part of the project. The panel of experts produced the following key recommendations that were graded according to the strength of evidence and clinical judgement. The first-line therapy for non-MALT primary lung non-Hodgkin's lymphomas should include anthracycline-based chemotherapy with CHOP or CHOP-like, MACOP-B or MACOP-B-like regimens (grade D). Rituximab association with chemotherapy needs to be evaluated within approved clinical trials. Second-line therapy with high-dose chemotherapy and autologous stem cell transplantation is recommended (grade B). In patients with MALT primary lung non-Hodgkin's lymphomas, the recommended first-line therapy should include chlorambucil, CHOP, CHOP-like or fludarabine-containing regimens (grade B). Radiotherapy is to be reserved for patients with a unique, small lesion in a poorly mobile site and with contraindication to surgery (grade D). Rituximab should be administered only within approved clinical trials. For treatment of primary mediastinal large B-cell lymphomas, the recommended first-line therapy is a chemotherapy and radiotherapy association (grade B). An anthracycline-based chemotherapy with CHOP, MACOP-B or VACOP-B is recommended (grade B). Rituximab combination with chemotherapy is highly suggested but only for patients enrolled into approved clinical trials. Patients with an inadequate early response should be candidates for early intensification with high-dose chemotherapy (grade C). Patients with refractory or relapsed disease should undergo rescue programs including intensive, non-cross-resistant debulking treatment followed, in chemosensitive patients, by high-dose chemotherapy and autologous stem cell transplantation (grade B).

show abstract

“…Vascular and bronchial wall infiltration, although suggestive of lymphoma, was seen in cases of nodular amyloidoma (16,17). Pleural infiltration, however, was exclusively limited to the lymphomas (18,19). Whereas the amyloidomas contained scattered plasma cells and small round lymphocytes, the lymphomas tended to have either a monotonous population of small round lymphocytes with plasma cell differentiation or the characteristic heterogeneity of MALT type lymphomas with small round lymphocytes, centrocyte-like cells, monocytoid lymphocytes, and plasma cells.…”

Section: Discussionmentioning

confidence: 99%

Nodular Amyloidoma and Primary Pulmonary Lymphoma with Amyloid Production: A Differential Diagnostic Problem

2000

View full text Add to dashboard Cite

Nodular amyloidomas (NA) of the lung are nonneoplastic inflammatory nodules containing eosinophilic amyloid deposits and a lymphoplasmacytic infiltrate. In some instances, the extensive amyloid deposits may obscure an underlying lymphoproliferative disorder. The histologic and immunohistologic features that discriminate these two differential diagnostic possibilities were studied in this series of six cases of NA and five cases of primary low-grade malignant lymphomas of lung with secondary amyloid deposits (ML). Two of lymphoma cases showed histopathologic and immunophenotypic features of B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-cell CLL/SLL), and three cases were low-grade B-cell lymphoma derived from mucosa associated lymphoid tissue (MALT lymphoma). Key discriminating morphologic features between NA and ML included lymphatic tracking of the cellular infiltrate (3/5 ML; 1/6 NA), pleural infiltration (3/5 ML; 0/6 NA), sheet-like masses of plasma cells (5/5 ML; 0/6 NA) and reactive follicles (4/5 ML; 1/6 NA). Lesional circumscription, vascular and bronchial destruction, lymphoepithelial lesions, and granulomas were not helpful discriminators. Immunohistochemical features indicating a dominant CD20؉, CD79a؉ B-cell population (5/5 ML; 0/6 NA), light chain restriction (4/5 ML; 0/6 NA), and aberrant antigen expression of CD20/CD43 (2/5 ML; 0/6 NA) were helpful. Amyloid tumors with a reactive lymphoplasmacytic infiltrate can be separated from low-grade malignant lymphomas utilizing both histologic and immunohistochemical features.

show abstract

Primary non-Hodgkin's lymphoma and pseudolymphoma of lung: A study of 161 patients

Cited by 186 publications

References 27 publications

Pseudolymphoma of the liver associated with primary biliary cirrhosis: A case report and review of literature

Pseudolymphoma of the liver associated with primary biliary cirrhosis: A case report and review of literature

Nodular Amyloidoma and Primary Pulmonary Lymphoma with Amyloid Production: A Differential Diagnostic Problem

Contact Info

Product

Resources

About